Phase II trial of Encorafenib and Binimetinib in BRAFV600E-mutant NSCLC initiated
A Phase II study has been initiated to assess the efficacy of the BRAF inhibitor Encorafenib in combination with the MEK inhibitor Binimetinib in patients diagnosed with BRAFV600E-mutant metastatic Non-small Cell Lung Cancer (NSCLC).